Human papillomavirus vaccine recombinant nonavalent - Merck

Drug Profile

Human papillomavirus vaccine recombinant nonavalent - Merck

Alternative Names: 9-valent HPV vaccine - Merck and Co; 9-valent human papillomavirus vaccine - Merck and Co; 9vHPV vaccine - Merck; GARDASIL9; Human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; Human Papillomavirus 9-valent vaccine, Recombinant; Human papillomavirus vaccine recombinant 9-valent - Merck; Human papillomavirus vaccine-Merck-9 valent; Multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine - Merck; V-503

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Vulvovaginal cancer

Most Recent Events

  • 29 Jun 2018 Phase-III clinical trials in Human papillomavirus infections (In adolescents, In children, Prevention, In adults) in Vietnam (IM) (NCT03546842)
  • 15 Jun 2018 Merck & Co files an sBLA for approval of Human papillomavirus vaccine recombinant nonavalent, for the prevention of cancer and diseases caused by nine virus types
  • 13 Jun 2018 Merck plans a phase III trial for Human papillomavirus infections, Cervical cancer, Vulvovaginal cancer, Adenocarcinoma and Condylomata Acuminata (Prevention) in Vietnam in June 2018 (EudraCT2017-001205-33) (NCT03546842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top